Antikoagulation mit Rivaroxaban bei Livedovaskulopathie (RILIVA): Eine multizentrische, einarmige Open-label-, Phase-2a-, Proof-of-Concept-Studie

Translated title of the contribution: Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): A multicenter, single-arm, open-label, phase 2a, proof-of-concept trial

C. Weishaupt, A. Strölin, B. Kahle, A. Kreuter, S. W. Schneider, J. Gerss, M. Eveslage, A. Drabik, T. Görge*

*Corresponding author for this work
Translated title of the contributionAnticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): A multicenter, single-arm, open-label, phase 2a, proof-of-concept trial
Original languageGerman
JournalVasomed
Volume28
Issue number5
Pages (from-to)256-257
Number of pages2
ISSN0942-1181
Publication statusPublished - 09.2016

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Cite this